A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
Phase of Trial: Phase IV
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 07 Dec 2017 Planned patient number changed to 2240.
- 01 Dec 2017 Planned number of patients changed from 1000 to 1200.
- 05 Apr 2017 Trial design presented at the 108th Annual Meeting of the American Association for Cancer Research